Latest News
-
Landmark FTC Settlement Aims to Reduce Drug Costs for Patients
Read Article: Landmark FTC Settlement Aims to Reduce Drug Costs for PatientsThe Federal Trade Commission (FTC) has announced a landmark settlement with one of the nation’s largest pharmacy benefit managers, Express Scripts, aimed at significantly lowering prescription drug costs for American patients.
-
Legal Challenge Filed Over Proposed 340B Rebate Model
Read Article: Legal Challenge Filed Over Proposed 340B Rebate ModelHospital associations and safety-net health systems have filed a federal lawsuit seeking to block the Health Resources and Services Administration’s (HRSA) proposed 340B Rebate Model Pilot Program, which is scheduled to launch in January 2026.
-
Medicare Over Dispensing of Prescription Drugs and Its Impact
Read Article: Medicare Over Dispensing of Prescription Drugs and Its ImpactA recent Wall Street Journal investigation found that mail-order pharmacies significantly over-dispensed medications to Medicare patients, resulting in an estimated $3 billion in excess drugs between 2021 and 2023.
-
The Impact of Vertical Integration on Health Care Delivery and Costs: Evidence from Physician–pharmacy Integration
Read Article: The Impact of Vertical Integration on Health Care Delivery and Costs: Evidence from Physician–pharmacy IntegrationNew research from Pragya Kakani, PhD, sheds light on how physician–pharmacy integration is shaping the cost and delivery of high-cost oral cancer treatments. Using national Medicare data and a stacked event study design across 204 oncology practices, the study evaluates…
-
Community Oncology Is at a Tipping Point Thanks to Consolidation, Policy Problems
Read Article: Community Oncology Is at a Tipping Point Thanks to Consolidation, Policy ProblemsCommunity oncology is facing growing pressure from consolidation and policy challenges. In this article, Dr. Harsha Vyas outlines why independent practices are at a critical turning point and what must change to protect patient access.
-
Congressional Budget Office Finds the 340B Drug Pricing Program Costly for Taxpayers with Little Evidence It Reaches Patients
Read Article: Congressional Budget Office Finds the 340B Drug Pricing Program Costly for Taxpayers with Little Evidence It Reaches PatientsA recent report by the CBO confirms that the 340B program, which was originally designed to help safety-net hospitals and clinics buy outpatient drugs at a discount, is now imposing a major cost burden on taxpayers without clear proof that…